0
Abstract: Slide Presentations |

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), COMORBID DISEASE, AND FOLLOW-UP HOSPITALIZATIONS IN A U.S. COHORT FREE TO VIEW

David M. Mannino, MD*; Andrine Swensen, PharmD; Deborah Thorn, PharmD
Author and Funding Information

University of Kentucky, Lexington, KY


Chest


Chest. 2007;132(4_MeetingAbstracts):426b. doi:10.1378/chest.132.4_MeetingAbstracts.426b
Text Size: A A A
Published online

Abstract

PURPOSE: COPD is associated with important comorbid diseases, including cardiovascular disease, diabetes, and hypertension. We analyzed cross-sectional and longitudinal data from participants in the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS).

METHODS: We limited our analysis to 22,056 participants aged 45 and older at baseline on whom we had complete data. We stratified the sample based on prebronchodilator baseline lung function data, according to GOLD criteria, including a “restrictive” category (FEV1/FVC >70% and FVC < 80%). We identified subjects who, at baseline, had cardiovascular disease, diabetes, or hypertension. We then searched for the following outcomes over 5 years of follow-up: hospitalizations for heart disease, congestive heart failure, stroke, and death.

RESULTS: We found lung function impairment to be associated with more comorbid disease. In logistic regression models adjusting for age, sex, race, smoking status, body mass index and education, people with GOLD stage 3 or 4 COPD had a higher prevalence of cardiovascular disease (odds ratio [OR] 1.7, 95% confidence interval [CI] 1.3, 2.4), diabetes (OR 1.6, 95% CI 1.3, 2.0), and hypertension (OR 1.6, 95% CI 1.4, 1.9). Each comorbid disease was associated with a high rate of hospitalizations and mortality that was worse in people with impaired lung function (data for diabetes in Table).

CONCLUSION: Lung function impairment, in this population, is associated with a higher risk of cardiovascular disease, diabetes, and hypertension. In addition, the presence of these comorbid diseases is associated with an increased risk of hospitalizations for heart disease, congestive heart failure, stroke, and death.

CLINICAL IMPLICATIONS: Patients with respiratory impairment are at a higher risk for comorbid disease.

DISCLOSURE: David Mannino, No Product/Research Disclosure Information; University grant monies None; Grant monies (from sources other than industry) None; Grant monies (from industry related sources) Novartis, GlaxoSmithKline, Pfizer; Shareholder None; Employee None; Fiduciary position (of any organization, association, society, etc, other than ACCP None; Consultant fee, speaker bureau, advisory committee, etc. Pfizer, GlaxoSmithKline, Dey, Sepracor; Other None

Monday, October 22, 2007

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543